Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term follow-up study of sotatercept added to background therapy for pulmonary arterial hypertension
NL-OMON56380Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Adverse events, Anti-drug antibodies and 3 more. Started Oct 2022; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON56380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56380.